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In this issue of Neuron, Yin et al. (2013) demonstrate that overexpression of Neuregulin 1 causes synaptic
dysfunction and schizophrenia-like behavioral deficits. These abnormalities can be reverted by restoring
normal levels of Neuregulin 1, opening possibilities for the treatment of mental disease.Schizophrenia is a severe mental illness
that affects approximately 1% of the
population worldwide. Genetic factors
play a major role in the etiology of
schizophrenia, with an estimated herita-
bility of around 80%. Genetic variation
in Neuregulin 1 (NRG1) has been
repeatedly linked to the disorder in
multiple human populations. In partic-
ular, more than 80 single nucleotide
polymorphisms localized in noncoding
regions of this gene have been identified
(Mei and Xiong, 2008). These observa-
tions led to the hypothesis that expres-sion of NRG1 might be altered in
schizophrenia.
Alternative splicing of NRG1 generates
more than 30 isoforms classified in six
different types (I to VI) depending on their
structure (Mei and Xiong, 2008). They all
share an epidermal growth factor (EGF)-
like domain, which is required for the
activation of several members of the
ErbB family of receptor tyrosine kinases.
In schizophrenia, the expression of partic-
ular isoforms of NRG1 seems altered,
although reports are contradictory. For
example, several studies reported areduction in the levels of the isoform 1
alpha of NRG1 in the brain of schizo-
phrenia patients (e.g., Bertram et al.,
2007), while others showed elevated
levels of NRG1 in a particular risk haplo-
type (e.g., Weickert et al., 2012). Consis-
tent with this later view, several other
studies have shown increased NRG1
mRNA and protein levels in the hippo-
campus and prefrontal cortex of schizo-
phrenia patients (Hashimoto et al., 2004;
Petryshen et al., 2005). These contradic-
tory findings have been surprisingly repli-
cated in mice: both loss and gain of NRG178, May 22, 2013 ª2013 Elsevier Inc. 577
Figure 1. Synaptic Dysfunction by Overexpression of Type I NRG1
Overexpression of type I NRG1 in pyramidal cells (PCs) reduces mEPSC
frequencies and prepulse pair ratios, which leads to decreased vesicle release
in glutamatergic terminals (1). Overexpression of type I NRG1 also decreases
the amplitude of mIPSC due to a reduction in the number of GABAAalpha1
receptors (2). DOX treatment (+DOX) in the adult reverts NRG1 to basal levels
and restore synaptic function. eb, excitatory bouton; ib, inhibitory bouton; n,
nucleus; PC, pyramidal cell.
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Previewsfunction cause similar behav-
ioral phenotypes, including
impaired memory and
hyperactivity (Deakin et al.,





might cause some of the
synaptic deficits that are
commonly associated with
schizophrenia.
In this issue of Neuron, Yin
et al. (2013) tested this hy-
pothesis through a very
elegant strategy based on
the generation of mice in
which NRG1 is selectively
overexpressed in the brain.
Using the tetracycline-off
system (i.e., gene expression
in the absence of doxycy-
cline), Yin et al. (2013) gener-
ated mice in which overex-
pression of the type I NRG1
isoform (a cleavable, diffus-
ible protein) can be specif-
ically induced in pyramidal
cells of the cerebral cortex
and other neuronal popula-
tions of the forebrain, thereby
mimicking the elevated levels
found in schizophrenia pa-
tients. Consistent with previ-
ous reports based on a broad
NRG1 overexpression model
(Deakin et al., 2012), Yin
et al. (2013) found that exac-
erbated NRG1 levels in the
forebrain from early postnatal
stages cause some key
schizophrenia-relatedbehavioral deficits, such as hyperactivity
and impaired sensorimotor gating, social
behavior, and cognitive function. Yin
et al. (2013) found that these alterations
are primarily due to glutamatergic hypo-
function, as revealed by a pronounced
reduction in field excitatory postsynaptic
potentials in the Shaffer collateral
pathway of the hippocampus.
Since type I NRG1 is secreted, overex-
pression of this protein could lead to
glutamatergic hypofunction through both
cell and non-cell-autonomous mecha-
nisms. Using a comprehensive array of
electrophysiological measurements, Yin578 Neuron 78, May 22, 2013 ª2013 Elsevieret al. (2013) found that the defects in glu-
tamatergic neurotransmission are prob-
ably due to impaired glutamate release
rather than to postsynaptic defects. For
example, no defects were found in the
amplitude of miniature excitatory post-
synaptic currents (mEPSCs), but both
mEPSC frequencies and paired-pulse
ratios were altered in mice with type I
NRG1 overexpression. The effect of
excessive NRG1 signaling on excitatory
vesicle release seems to be mediated by
changes in the cytoskeleton (Figure 1).
They found that NRG1 overexpression
increases the levels of synaptic LIMInc.domain kinase 1 (LIMK1),
which in turn phosphorylates
and, as a result, inactivates
cofilin, a protein that modu-
lates vesicle fusion at the
active zone through the regu-
lation of the actin depolymer-
ization (Arber et al., 1998;
Morales et al., 2000). This is
an important step forward in







also alters GABAergic neuro-
transmission in the cortex
but in a different manner. Yin
et al. (2013) found no pre-
synaptic abnormalities in
GABAergic connections.
However, they observed a
decrease in the amplitude of
miniature inhibitory postsyn-
aptic currents (mIPSCs) and
a reduction in expression of
GABAAa1 receptors in pyra-
midal cells, both consistent
with a postsynaptic defect in
inhibitory neurotransmission
inmice with type I NRG1 over-
expression (Figure 1). These
results are intriguing, because
overexpression of type III
NRG1 in pyramidal cells
enhances the number of
GABAergic synapses con-
tacting these neurons (Fazzari
et al., 2010). Thus, it seems
that membrane-bound (type
III) and diffusible (type I) iso-forms of NRG1 differentially influence
GABAergic circuits through the modula-
tion of independent presynaptic and post-
synaptic mechanisms, respectively.
The most plausible explanation for the
differential effects of the various NRG1
isoforms in overexpression experiments
is that they are mediated by different re-
ceptors. Consistent with this idea, Yin
et al. (2013) found that the ErbB4 receptor
does not mediate the defects found in
pyramidal cells after overexpression of
type I NRG1. Indeed, ErbB4 seems to be
exclusively expressed by interneurons in
rodents (Fazzari et al., 2010; Vullhorst
Neuron
Previewset al., 2009), and so the function of type I
NRG1 must necessarily be mediated by
another receptor in pyramidal cells. How-
ever, how is it possible that overexpres-
sion of type I NRG1 in the postnatal
cortex does not directly affect
GABAergic interneurons? This isoform
of NRG1 plays an important role in the
guidance of interneurons during embry-
onic development, in a process that is
also dependent on ErbB4 function
(Flames et al., 2004), and so interneurons
are in principle ‘‘geared up’’ to respond
to this signal. One possibility is that bind-
ing of type I NRG1 to interneurons re-
quires an additional partner that is not
present in the postnatal cortex. Alterna-
tively, the formation of inhibitory synap-
ses might be exclusively dependent on
a membrane-bound NRG1 isoform.
Consistent with this idea, expression of
the diffusible type I NRG1 isoform is
very low in postnatal cerebral cortex
(Fazzari et al., 2010), which suggests
that this protein is unlikely to play a major
role in the normal process of synapto-
genesis. At any rate, these various pieces
of evidence suggest that different iso-
forms of NRG1 play different roles at
different stages of development and in
the adult, and so the temporal and spatial
regulation of their expression might be
key for activation of specific signaling
pathways.
The beauty of the approach followed
by Yin et al. (2013) is that their genetic
model allowed them to address two
additional questions related to the key
issue of the temporal regulation of
NRG1 expression. First, they asked
whether the timing of overexpression in-
fluences the behavioral outcome. To
this end, they treated their transgenic
mice with doxycycline during the first 8
postnatal weeks, which effectively
delayed the abnormal rise in NRG1 levels
until 11 weeks of age. They found that
overexpression of type I NRG1 in young
adult mice is sufficient to induce excit-
atory synaptic defects and equivalent
behavioral deficits to those found in
mice with continuous overexpression of
NRG1 since the first postnatal days.
These results demonstrate that the effectof NRG1 overexpression is not neces-
sarily dependent on an early role of this
protein during development.
Second, they investigate the revers-
ibility of the behavioral deficits elicited
by the overexpression of NRG1 through
the restoration of its normal levels. In brief,
Yin et al. (2013) treated transgenic mice
displaying behavioral deficits due to over-
expression of type I NRG1 with doxycy-
cline, which effectively turned off the
ectopic expression of this protein. Sur-
prisingly, Yin et al. (2013) found that
bringing back type I NRG1 to their endog-
enous levels in adult mice restores normal
synaptic function in glutamatergic axon
terminals and rescues the behavioral
abnormalities (Figure 1). These results
are conceptually important, because
they add further support to the idea that
therapeutic interventions in the adult brain
may restore synaptic function, as previ-
ously suggested for animal models of
fragile X and Rett syndromes (Do¨len
et al., 2007; Guy et al., 2007).
In sum, the results of the experiments
carried out by Yin et al. (2013) indicate
that overexpression of type I NRG1 may
cause schizophrenia-related behavioral
deficits in mice. It should be noted, how-
ever, that both increased and decreased
NRG1 signaling has been reported in
patients with schizophrenia (Bertram
et al., 2007; Hashimoto et al., 2004; Pet-
ryshen et al., 2005). In addition, increased
expression of the CYT-1 isoform of the
ERBB4 receptor in humans carrying poly-
morphisms in this gene causes a counter-
intuitive downregulation of this signaling
pathway (Law et al., 2012). Thus, it is
conceivable that function of NRG1
signaling in the cerebral cortex depends
on a delicate balance in the expression
of the different NRG1 isoforms and their
receptors. An alteration of their normal
expression patterns, in any direction,
may disturb cortical functioning and lead
to similar behavioral abnormalities.
Understanding the precise function of
each of the different isoforms of NRG1
and their receptors may shed light into
this process. The development of new
animal models based on these discov-
eries, and their subsequent analysis,Neuronshould also fuel discoveries in this area
and unravel potential therapeutic targets.
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